Benefits of Triple-Combo Trikafta for CF Mostly Due to Elexacaftor

Benefits of Triple-Combo Trikafta for CF Mostly Due to Elexacaftor

295637

Benefits of Triple-Combo Trikafta for CF Mostly Due to Elexacaftor

The therapeutic benefits of the triple-combination medication Trikafta are mostly due to the effects of elexacaftor, a next-generation corrector of CFTR, the faulty protein in cystic fibrosis (CF), a study has found. These findings suggest that new combinations with elexacaftor may be even more effective than Trikafta. Trikafta, marketed by Vertex Pharmaceuticals and approved in the U.S. in 2019, combines elexacaftor, tezacaftor, and ivacaftor, and was designed to treat 90% of CF patients. Notably, the combined…

You must be logged in to read/download the full post.